Work

Optimizing Second-Line Therapy for Drug-Resistant Tuberculosis: the Additive Value of Sequencing for Multiple Resistance Loci

Year: 2011

Type: letter

Abstract: Molecular probe-based assays for common resistance mutations to isoniazid and rifampin (multidrug-resistant tuberculosis [MDR-TB]) are of considerable clinical value ([1][1], [2][2]), and yet once MDR-TB has been identified, the more vexing challenge arises of determining a regimen of several

Source: Antimicrobial Agents and Chemotherapy

DOI: 10.1128/aac.00332-11

Authors: Scott K. Heysell, Eric R. Houpt

Institution: University of Virginia

Language: English

Topic: Tuberculosis Research and Epidemiology

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Institute of Allergy and Infectious Diseases